Hypoxic tumour‐derived exosomal miR ‐1290 exacerbates the suppression of CD8 + T cells by promoting M2 macrophage polarization
Immunology · 2024-12 · 173 (4) · 672-688
DOI: 10.1111/imm.13853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 26.08.2024. Verfasst von Yeni Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: MicroRNAs, Exosomes, CD8-Positive T-Lymphocytes, Liver Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, the Science and Technology Program of Shinan District of Qingdao City.
Abstract (Originalsprache)
Hypoxia plays an important role in the metastasis of hepatocellular carcinoma (HCC). Exosomes have been widely studied as mediators of communication between tumours and immune cells. However, the specific mechanism by which hypoxic HCC cell‐derived exosomes suppress antitumor immunity is unclear. Hypoxia scores were determined for The Cancer Genome‐Liver Hepatocellular Carcinoma (TCGA‐LIHC) dataset patients, and HCC patients in the hyperhypoxic group had a higher degree of M2 macrophage infiltration. Patients in the M2 high‐invasion group had a lower probability of survival than those in the low‐invasion group. In vivo and in vitro experiments demonstrated that exosomes secreted by hypoxic HCC cells promote M2 macrophage polarization. This polarization induces apoptosis in CD8+ T cells. Additionally, it encourages epithelial–mesenchymal transition (EMT), which increases HCC migration. Exosomal miRNA sequencing revealed that miR‐1290 was highly expressed in exosomes secreted by hypoxic HCC cells. Mechanistically, miR‐1290 in macrophages inhibited Akt2 while upregulating PD‐L1 to promote M2 polarization, induce apoptosis in CD8 + T cells, and enhance EMT in HCC. Animal studies found that the miR‐1290 antagomir in combination with the immune checkpoint inhibitor produced better antitumor effects than the monotherapies. In conclusion, the secretion of exosome‐derived miR‐1290 from HCC cells in a hypoxic environment supported immune escape by HCC cells by promoting M2 macrophage polarization to induce apoptosis in CD8 + T cells and enhance EMT that promoted HCC metastasis. Therefore, miR‐1290 is an important molecule in antitumor immunity in HCC, and inhibition of miR‐1290 could provide a novel immunotherapeutic approach for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Transplantation, Affiliated Hospital of Qingdao University, Qingdao, China.
ORCID-Profile: Yeni Yang
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- the Science and Technology Program of Shinan District of Qingdao City
Zitieren
APA
Yang, Y., Wu, T., Wang, Y., Luo, D., Zhao, Z., Sun, H., Zhang, M., Zhang, B., & Han, B. (2024). Hypoxic tumour‐derived exosomal miR ‐1290 exacerbates the suppression of CD8 + T cells by promoting M2 macrophage polarization. Immunology, 173(4), 672-688. https://doi.org/10.1111/imm.13853
Vancouver
Yang Y, Wu T, Wang Y, Luo D, Zhao Z, Sun H, et al. Hypoxic tumour‐derived exosomal miR ‐1290 exacerbates the suppression of CD8 + T cells by promoting M2 macrophage polarization. Immunology. 2024;173(4):672-688. doi:10.1111/imm.13853
BibTeX
@article{Yang2024,
author = {Yang, Yeni and Wu, Tiansong and Wang, Youpeng and Luo, Dingan and Zhao, Ziyin and Sun, Hongfa and Zhang, Mao and Zhang, Bin and Han, Bing},
title = {Hypoxic tumour‐derived exosomal miR ‐1290 exacerbates the suppression of CD8 + T cells by promoting M2 macrophage polarization},
journal = {Immunology},
year = {2024},
volume = {173},
number = {4},
pages = {672--688},
doi = {10.1111/imm.13853}
}
EUVIMED